SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001837607-24-000066
Filing Date
2024-05-16
Accepted
2024-05-16 16:27:47
Documents
14
Period of Report
2024-05-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K aeon-20240516x8k.htm   iXBRL 8-K 40820
  Complete submission text file 0001837607-24-000066.txt   174281

Data Files

Seq Description Document Type Size
2 EX-101.SCH aeon-20240516.xsd EX-101.SCH 4043
3 EX-101.DEF aeon-20240516_def.xml EX-101.DEF 2868
4 EX-101.LAB aeon-20240516_lab.xml EX-101.LAB 17852
5 EX-101.PRE aeon-20240516_pre.xml EX-101.PRE 10674
17 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20240516x8k_htm.xml XML 5048
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

IRS No.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40021 | Film No.: 24956008
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)